ACTRN12624001047583尚未招募1 期
A two-part, Phase 1/2, open label study to evaluate tumour cell death using CDI-DX001 positron emission tomography/computed tomography (PET/CT) as a prognostic disease marker, a measure of response to neoadjuvant therapy and, as a potential novel theranostic treatment modality in pancreatic ductal adenocarcinoma (PDAC) patients
Amplificare Pty Ltd0 个研究点目标入组 120 人开始时间: 2024年8月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Male or female participants (or LAR) have voluntarily agreed to study participation by giving written informed consent and must be greater or equal to 18 years of age on the day of signing the informed consent form (ICF).
- •2. Participants with newly diagnosed histologically or cytologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) from one of the following 3 patient groups:
- •a. Group 1: Patients with borderline resectable (BR) disease with intent to undergo neoadjuvant chemotherapy (NAC) ± radiotherapy (RT).
- •b. Group 2: Patients with locally advanced unresectable disease with intent to undergo systemic treatment ± radiotherapy (RT).
- •c. Group 3: Patients with metastatic disease with intent to receive systemic treatment.
- •3. Participants must have radiologically measurable disease as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Eisenhauer 2009) at screening, with PDAC primary lesion greater or equal to 2 cm in maximum transaxial dimension (for Group 1 and Group 2) OR at least one lesion greater or equal to 2 cm in maximum transaxial dimension (for Group 3) based on pre-study morphological imaging evidence (FDG PET/CT, CT or MRI), not older than 30 days at screening.
- •4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of =1 at screening.
- •5. Life expectancy greater or equal to 12 weeks at screening according to investigator’s best judgement.
- •6. Adequate renal function characterised by estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m^2.
- •7. Female participants are eligible to enter and participate in the study if they are of:
- •a. Nonchildbearing potential.
- •b. Childbearing potential as defined in Appendix 1 of the protocol, with a negative pregnancy test at screening and within 7 days of the first CDI-DX001 PET/CT scan and agree to use contraception for the duration of the CDI-DX001 PET/CT imaging period.
- •c. Not breastfeeding.
- •8. Male participants who are sexually active with a woman of child bearing potential are eligible to enter and participate in the study if they are vasectomised or agree to the use of
- •contraception (as defined in Appendix 1 of the protocol) for the duration of the CDI-DX001 PET/CT imaging period.
排除标准
- •1. Female participants who are pregnant or lactating.
- •2. Participants receiving:
- •a. Any prior systemic chemotherapy.
- •b. Biologic therapy (i.e., antibodies), continuous or intermittent small-molecule therapies, or any other investigational agents within a period of 5 times the half life of the agent or within 4 weeks (whichever is shorter) prior to day of first CDI-DX001 PET/CT scan.
- •c. For participants with borderline resectable (BR)-Pancreatic Ductal Adenocarcinoma (PDAC) or locally advanced (LA)-PDAC, any prior curative or palliative radiotherapy (RT).
- •d. For participants with metastatic PDAC, prior curative or palliative radiation therapy to all measurable sites of disease > 2 cm (i.e. no assessable sites of disease >2 cm which have not received radiotherapy (RT)).
- •e. Any major surgery within 4 weeks prior to the day of first CDI-DX001 PET/CT scan.
- •3. Known or suspected hypersensitivity to CDI-DX001 or any of its components.
- •4. Concurrent participation in another therapeutic clinical trial.
- •5. Exposure to any radiopharmaceutical with a half-life greater than 99mTc within up to 7 days prior to the first planned administration of CDI-DX001 dependent on the radioisotope (e.g., if 18F, 68Ga or 99mTc up to 16 hours is sufficient).
- •6. Active uncontrolled infection at screening.
- •7. Congestive heart failure or prior cardiac disease per New York Heart Association Classification III or IV.
- •8. Uncontrolled hypertension (systolic blood pressure [BP] >180 mmHg or diastolic BP >100 mmHg)
- •9. Any active malignancy less or equal to 3 years before the first CDI-DX001 PET/CT scan except for the specific cancer under investigation in this study or any localised or noninvasive cancer that has been treated curatively (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, treated early stage melanoma, or carcinoma in situ of the prostate, cervix or breast).
- •10. Any other unstable, preexisting major medical condition that in the opinion of the investigator contraindicates the use of CDI-DX001, or otherwise renders the participant unfit for the study, in the opinion of the investigator, after medical interview, physical examination, and/or screening investigations.
研究者
相似试验
进行中（未招募）
1 期
Clinical Trial to evaluate Effects and Safety of Olaptesed Pegol or Olaptesed Pegol/Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic CancerColorectal cancer with liver metastasesPancreatic cancer with liver metastasesMedDRA version: 20.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003657-15-DEOXXON Pharma AG20
终止
1 期
A study of a new combination of drugs (cetuximab, cobimetinib and palbociclib) in subjects with advanced or metastatic colorectal cancer who have failed all available standard therapiesCancer - Bowel - Back passage (rectum) or large bowel (colon)Colorectal CancerACTRN12621001436864Cothera Bioscience Pty ltd3
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDMedDRA version: 26.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-DESanofi-Aventis Recherche & Developpement109
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDMedDRA version: 21.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-NLSanofi-Aventis Recherche & Developpement109
进行中（未招募）
1 期
Mechanistic study of the effect of itepekimab on airway inflammation in patients with COPDChronic Obstructive Pulmonary DiseaseEUCTR2021-001654-65-DKSanofi-Aventis Recherche & Developpement109